Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy

Breast

Volumn 21, Issue 4, 2012, Pages 464-467

  Chaumard, N ^a   Limat, S ^b,c   Villanueva, C ^d   Nerich, V ^b,c   Fagnoni, P ^e   Bazan, F ^d   Chaigneau, L ^d   Dobi, E ^d   Cals, L ^d   Pivot, X ^d,f  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^c Laboratory of Pharmaceutical Engineering   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

Author keywords

Adjuvant chemotherapy; Anemia; Breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; HEMOGLOBIN; TAXANE DERIVATIVE;

ADULT; AGE; ANEMIA; ARTICLE; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; DRUG MEGADOSE; EARLY CANCER; FRANCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; UNIVERSITY HOSPITAL;

EID: 84863860815     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.10.009     Document Type: Article

References (29)

1. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007 Jul, 18(7):1133-1144.
2. Citron Ml, Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21(8):1431-1439.
3. Eifel P., Axelson J.A., Costa J., Crowley J., Curran W.J., Deshler A., et al. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001 Jul 4, 93(13):979-989.
4. Roche H., Fumoleau P., Spielmann M., Canon J.L., Delozier T., Serin D., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006 Dec 20, 24(36):5664-5671.
5. Martin M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J.P., Weaver C., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352(22):2302-2313.
6. Groopman J.E., Itri L.M. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999 Oct 6, 91(19):1616-1634.
7. Lind M., Vernon C., Cruickshank D., Wilkinson P., Littlewood T., Stuart N., et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002 Apr 22, 86(8):1243-1249.
8. Ludwig H., Van Belle S., Barrett-Lee P., Birgegard G., Bokemeyer C., Gascon P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004 Oct, 40(15):2293-2306.
9. Bokemeyer C., Aapro M.S., Courdi A., Foubert J., Link H., Osterborg A., et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007 Jan, 43(2):258-270.
10. Hedenus M., Adriansson M., San Miguel J., Kramer M.H., Schipperus M.R., Juvonen E., et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003, 122(3):394-403.
11. Henke M., Laszig R., Rube C., Schafer U., Haase K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 Oct 18, 362(9392):1255-1260.
12. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003, 4(8):459-460.
13. Bohlius J., Schmidlin K., Brillant C., Schwarzer G., Trelle S., Seidenfeld J., et al. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009, (3):CD007303.
14. Aapro M., Scherhag A., Burger H.U. Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008 Jul 8, 99(1):14-22.
15. Glaspy J., Degos L., Dicato M., Demetri G.D. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 2002, 7(2):126-135.
16. Greil R., Thodtman R., Roila F. Erythropoietins in cancer patients: ESMO recommendations for use. Ann Oncol 2008, 19(Suppl. 2):ii113-115.
17. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008 Jan 1, 26(1):132-149.
18. Gianni L., Cole B.F., Panzini I., Snyder R., Holmberg S.B., Byrne M., et al. Anemia during adjuvant non-taxane chemotherapy for early breast cancer: incidence and risk factors from two trials of the International Breast Cancer Study Group. Support Care Cancer 2008 Jan, 16(1):67-74.
19. Denison U., Baumann J., Peters-Engl C., Samonigg H., Krippl P., Lang A., et al. Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapy. Breast Cancer Res Treat 2003 Jun, 79(3):347-353.
20. Barrett-Lee P., Bokemeyer C., Gascon P., Nortier J.W., Schneider M., Schrijvers D., et al. Management of cancer-related anemia in patients with breast or gynecologic cancer: new insights based on results from the European Cancer Anemia Survey. Oncologist 2005 Oct, 10(9):743-757.
21. Repetto L. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer. Crit Rev Oncol Hematol 2009, 72(2):170-179.
22. Jones S.E., Savin M.A., Holmes F.A., O'Shaughnessy J.A., Blum J.L., Vukelja S., et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006 Dec 1, 24(34):5381-5387.
23. 2) in the FEC regimen. Ann Oncol 1997, 8(2):155-162.
24. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin. J Clin Oncol 1988, 6(6):976-982.
25. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. J Clin Oncol 1988, 6(4):679-688.
26. Coiffier B., Guastalla J.P., Pujade-Lauraine E., Bastit P. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001 Sep, 37(13):1617-1623.
27. Dranitsaris G., Clemons M., Verma S., Lau C., Vincent M. Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 2005 Nov, 6(11):856-863.
28. Nieboer P., Buijs C., Rodenhuis S., Seynaeve C., Beex L.V., van der Wall E., et al. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 2005 Nov 20, 23(33):8296-8304.
29. Fagnoni P., Limat S., Chaigneau L., Guardiola E., Briaud S., Schmitt B., et al. Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer. Support Care Cancer 2006 Oct, 14(10):1030-1037.